Quarterly history
AUM ($B)fundS&P 500(gap = α)/ Flow in/out
Behavior signals (lifetime)
Dip response
-17.26%
trims when stocks drop
when a holding falls −10%+
Middle response
-6.71%
baseline attrition
Rally response
+1.33%
adds into rallies
when a holding rises +10%+
Top positions · 30
| Ticker | $ value | % port | YoY | Hold time |
|---|---|---|---|---|
| SBILSimplify Government Mone | $4.61B | 71.5% | — | 0.8 yr |
| IVViShares Core S&P 500 ETF | $713M | 11.1% | — | 5.5 yr |
| AGGiShares Core U.S. Aggreg | $407M | 6.3% | — | 4.3 yr |
| TUASimplify Short Term Trea | $117M | 1.8% | — | 2.5 yr |
| SPUCSimplify US Equity PLUS | $72M | 1.1% | — | 1.3 yr |
| QISSimplify Multi-QIS Alter | $46M | 0.7% | — | 2.5 yr |
| BUCKSimplify Treasury Option | $40M | 0.6% | — | 2.3 yr |
| NMBSimplify National Muni B | $38M | 0.6% | — | 1.8 yr |
| PAGPPlains GP Holdings, L.P. | $31M | 0.5% | +23.4% | 3.3 yr |
| IBITiShares Bitcoin Trust ET | $27M | 0.4% | — | 0.8 yr |
| NXTISimplify NEXT Intangible | $24M | 0.4% | — | 2.0 yr |
| UTHRUnited Therapeutics Corp | $20M | 0.3% | +92.4% | 2.0 yr |
| ALGNAlign Technology, Inc. | $18M | 0.3% | +7.9% | 1.0 yr |
| LLYEli Lilly and Company | $15M | 0.2% | +12.2% | 4.5 yr |
| XVSimplify Target 15 Distr | $15M | 0.2% | — | 1.0 yr |
Portfolio composition (YoY)
Industry mix
Asset Management93.2%+3.0pp$6.00B
Asset Management - Leveraged1.8%$117M
Biotechnology1.3%-1.4pp$84M
Drug Manufacturers - General0.8%-0.5pp$54M
Medical - Devices0.5%-0.2pp$33M
Oil & Gas Midstream0.5%-0.9pp$31M
Unknown0.3%-0.0pp$22M
Medical - Diagnostics & Research0.3%-0.6pp$17M
Medical - Healthcare Information Services0.2%$10M
Industrial - Pollution & Treatment Controls0.1%-0.0pp$9M
Country
US99.1%-0.3pp
Unknown0.3%-0.0pp
DK0.2%
IE0.2%
GB0.1%+0.1pp
CR0.0%+0.0pp
CA0.0%-0.0pp
FR0.0%-0.1pp
Top 5: 91.8% · Top 10: 94.7% · Top 25: 97.5%
Top buys this quarter · 15
| NVO Novo Nordisk A/S | +$11M |
| TMO Thermo Fisher Scientific Inc. | +$6M |
| UTHR United Therapeutics Corporatio | +$6M |
| MMM 3M Company | +$6M |
| ABBV AbbVie Inc. | +$5M |
| AZN AstraZeneca PLCnew | +$5M |
| GILD Gilead Sciences, Inc. | +$3M |
| JNJ Johnson & Johnson | +$3M |
| CORT Corcept Therapeutics Incorporanew | +$2M |
| OXLC Oxford Lane Capital Corp.new | +$1M |
Top sells this quarter · 15
| UNH UnitedHealth Group Incorporate | −$26M |
| APLS Apellis Pharmaceuticals, Inc.exit | −$22M |
| REGN Regeneron Pharmaceuticals, Inc | −$16M |
| AMGN Amgen Inc. | −$13M |
| LLY Eli Lilly and Company | −$10M |
| MRK Merck & Co., Inc. | −$5M |
| PEN Penumbra, Inc.exit | −$5M |
| VRTX Vertex Pharmaceuticals Incorpo | −$4M |
| JAZZ Jazz Pharmaceuticals plc | −$4M |
| MLYS Mineralys Therapeutics, Inc.exit | −$3M |
Quarterly history (TTM returns)
| Period | AUM | # Pos | Return (1yr) | SPY (1yr) | Alpha (1yr) | Flow |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6.44B | 140 | +22.25% | +17.59% | +4.66% | +0.66B |
| 2025-12-31 | $6.03B | 138 | +23.38% | +17.72% | +5.66% | +0.81B |
| 2025-09-30 | $4.85B | 124 | +6.31% | +17.52% | -11.20% | +3.11B |
| 2025-06-30 | $1.54B | 85 | -0.53% | +14.94% | -15.47% | -0.59B |
| 2025-03-31 | $2.03B | 89 | -8.11% | +8.30% | -16.41% | +0.74B |
| 2024-12-31 | $1.33B | 87 | +9.45% | +24.89% | -15.43% | +0.08B |
| 2024-09-30 | $1.34B | 101 | +29.65% | +36.04% | -6.39% | +0.25B |
| 2024-06-30 | $1.04B | 98 | +15.77% | +24.49% | -8.72% | +0.13B |
| 2024-03-31 | $939M | 95 | +29.31% | +29.62% | -0.31% | +0.32B |
| 2023-12-31 | $533M | 99 | +2.86% | +26.18% | -23.31% | -0.06B |
| 2023-09-30 | $541M | 103 | +0.31% | +21.57% | -21.26% | +0.03B |
| 2023-06-30 | $537M | 103 | +4.19% | +19.42% | -15.24% | -0.06B |
| 2023-03-31 | $553M | 103 | -17.01% | -7.82% | -9.19% | +0.01B |
| 2022-12-31 | $590M | 68 | +7.11% | +7.56% | -0.45% | -0.18B |
| 2022-09-30 | $718M | 62 | -2.01% | -4.93% | +2.92% | -0.06B |
| 2022-06-30 | $798M | 60 | -13.68% | -16.11% | +2.43% | +0.00B |